Pharmaceuticals

Mylan NV could face decline in profitability in 2017 and 2018

Mylan NV faces decline in profitability in 2017 and 2018

Generic drug maker Mylan NV admitted on Wednesday that delays in the launch of some of its new drugs in addition to eroding prices for generics in the U.S. could hurt its profitability in 2017 as well as in 2018.

Due to uncertain U.S. regulatory environment, Mylan NV pushed back the launch of its key drugs in the U.S. to 2018.

David Maris, an analyst with Wells Fargo, said, “It’s clear they can’t achieve it. The fact they can’t make that tells you things must be bad. The $6 number has had a long and questionable history in my book.”

Location: 
Company: 

Valeant Pharmaceuticals International comes under fresh scrutiny

Valeant Pharmaceuticals International comes under fresh scrutiny

Valeant Pharmaceuticals International said on late Wednesday that it had got 2 federal subpoenas related to its pricing, distribution and patient support practices. The drug maker has come under fire for aggressively raising the prices of its drugs.

FDA seeks large clinical trial of testosterone products

FDA seeks large clinical trial of testosterone products

It has been reported that US Food and Drug Administration (FDA) is asking companies, which manufacture testosterone products, for conducting a large clinical trial in order to find out t benefits and risks associated with use of the hormone.

Christine Nguyen, MD, of the FDA, and colleagues said in a New England Journal of Medicine perspective that their agency is calling testosterone drug makers for making efforts together on one large controlled trial.

Location: 
Company: 

Anthem Offers Free Identity Theft Protection to Its Present and Former Customers

Anthem Offers Free Identity Theft Protection to Its Present and Former Customers

It has been reported that healthcare plans provider Anthem is offering several different levels of free identity theft protection to its present and former customers.

Company: 

Valeant reaches Tentative Deal to Buy Provenge from Dendreon

Valeant reaches Tentative Deal to Buy Provenge from Dendreon

On Thursday, Quebec-based Valeant Pharmaceuticals International Inc. announced that it has entered into a stalking-horse agreement with Dendreon Corp. to buy its prostate- cancer drug Provenge and other assets for $296 million in cash.

As per the tentative deal, Valeant is the preferred bidder. If the company's bid does not win the auction then it would receive breakup fee and reimbursed expenses. Valeant also said that a bankruptcy court would be required to approve Valeant's stalking-horse bid and the sale.

Location: 

Aetna signs deal with Gilead Sciences Inc.

Aetna

Aetna inc., health care company, on Friday announced that it has signed a deal with Gilead Sciences Inc., to make new hepatitis C drugs for customers with liver-destroying virus.

Location: 
Company: 

Brazil tests new dengue vaccine successfully

Brazil tests new dengue vaccine successfully

A team of medical experts in Brazil has tested a new dengue vaccine, which was successful in alleviating the disease.

Location: 
Company: 

Astrazeneca’s Experimental Drug to Treat COPD Fails to Reduce Acute Exacerbations

Astrazeneca’s Experimental Drug to Treat COPD Fails to Reduce Acute Exacerbation

On Monday, AstraZeneca PLC announced that Phase IIa study of benralizumab, an experimental drug for the treatment of Chronic Obstructive Pulmonary Disease (COPD), was published in 'The Lancet Respiratory Medicine' medical journal.

This drug is specially designed for the patients who do not respond effectively to the traditionally available inhalers. COPD is a disease related to smoking.

Location: 
Laboratories: 
Company: 

Evidence Turning in Favor of Gilead’s HCV Drug, Sovaldi

Evidence Turning in Favor of Gilead’s HCV Drug, Sovaldi

A lot of discussion is taking place in the US about Gilead's Hepatitis C (HCV) drug, Sovaldi. The major controversy surrounding the drug is its cost, which is $84,000 in the U. S. for a full course of treatment. Insurers and pharmacy benefit managers (PBMs) are quite angry over the price of the drug and find it quite costly.

On the other hand, the UK's National Institute for Health and Care Excellence (NICE) has lately given approval to the drug as being cost-effective. It has recommended the drug for sub-groups of patients.

Location: 
Company: 

Pfizer Faces Multiple Lipitor Lawsuits

Pfizer Faces Multiple Lipitor Lawsuits

American multinational pharmaceutical company Pfizer is under pressure after facing number of lawsuits related to the side effects of Lipitor.

Location: 
Company: 

Pages

Popular Stories

Facebook preparing to demote slow-loading stories on News Feed

Facebook, the world’s largest social network, is... Read More

Facebook reportedly working on dedicated video chat device

Social-networking giant Facebook is reportedly... Read More

Mario Draghi was right in keeping inflation expectations low

The European Central Bank’s president, Mario Draghi... Read More

Sprint reportedly proposes merger with Charter

Seeking an alternative to a deal with T-Mobile USA... Read More

Barclays results depict bleak picture of South African economy

Johannesburg-based Barclays Africa Group’s... Read More

Barclays Africa reports decline in first-half income

Barclays Africa Group Limited on Thursday reported... Read More